Related Experiment Videos
Current Perspectives on STING Agonists for Anticancer Drug Development
1Edirne Sultan 1. Murat State Hospital, Republic of Türkiye Ministry of Health, Edirne, Türkiye.
Chemical Biology & Drug Design
|July 27, 2026
Summary
The cyclic GMP-AMP (cGAS) synthase and stimulator of interferon genes (STING) pathway is crucial for cancer immunity. This review analyzes 60 STING agonists, identifying structural features for improved cancer therapy.
Area of Science:
- Immunology
- Oncology
- Drug Discovery
Background:
- The cGAS-STING pathway bridges innate and adaptive immunity in cancer.
- Activation by cytosolic DNA triggers type I interferons and cytokines, enhancing antitumor responses.
- Current STING agonists have limitations like poor pharmacokinetics and toxicity.
Purpose of the Study:
- To analyze molecular design and structure-activity relationships (SAR) of STING agonists.
- To identify structural features associated with enhanced STING activation for cancer therapy.
- To guide the development of novel STING-targeted therapeutics.
Main Methods:
- Review of 60 synthetic STING agonists with diverse chemical scaffolds.
- Analysis of structure-activity relationship (SAR) data.
- Examination of molecular design approaches.
Main Results:
- Identified key structural features linked to enhanced STING activation.
- Highlighted limitations of existing cyclic dinucleotide (CDN) and non-CDN STING agonists.
- Demonstrated the potential of specific scaffolds for improved agonist design.
Conclusions:
- Novel STING agonists require improved potency, selectivity, safety, and bioavailability.
- Understanding SAR is critical for developing effective STING-based cancer therapies.
- This review provides a foundation for discovering next-generation STING-targeted molecules.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...